Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer
This investigation did not reach its primary endpoint for any of the three treatment cohorts but does provide critical insight into the effects of combining nivolumab/relatlimab on the colorectal cancer tumor microenvironment and identifies subgroups that may derive greater benefit from this combination.
Authors
- Alexei Hernandez (ORCID: https://orcid.org/0000-0002-6044-2631)
- George Apostol (ORCID: https://orcid.org/0009-0009-5456-6142)
- Qingfeng Zhu (ORCID: https://orcid.org/0000-0001-7871-3359)
- Yiyang Gao (ORCID: https://orcid.org/0009-0005-4008-9841)
- Dung T. Le (ORCID: https://orcid.org/0000-0002-2110-7697)
- Jennifer N. Durham (ORCID: https://orcid.org/0000-0001-9097-9125)
- Michael J. Pishvaian (ORCID: https://orcid.org/0000-0002-1165-9041)
- Ilene Browner (ORCID: https://orcid.org/0000-0001-9914-6971)
- Daniel Shu
- Robert A. Anders (ORCID: https://orcid.org/0000-0002-2363-9072)
- Madelena Brancati (ORCID: https://orcid.org/0009-0009-2401-3694)
- Alens Valentin (ORCID: https://orcid.org/0009-0003-4348-4527)
- Ana De Jesus‐Acosta (ORCID: https://orcid.org/0000-0002-3225-3024)
- Daniel A. Laheru (ORCID: https://orcid.org/0000-0001-6646-0200)
- Nicolás J. Llosa
- Susan Petrie (ORCID: https://orcid.org/0009-0008-8570-1071)
- Won Jin Ho (ORCID: https://orcid.org/0000-0003-2644-5086)
- Eric S. Christenson (ORCID: https://orcid.org/0000-0001-5261-6083)
- Elizabeth M. Jaffee (ORCID: https://orcid.org/0000-0003-3841-6549)
- Franck Housseau (ORCID: https://orcid.org/0000-0002-7028-3953)
- Jiayun Lu (ORCID: https://orcid.org/0000-0002-5592-6658)
- Nilofer S. Azad (ORCID: https://orcid.org/0000-0002-9613-3988)
- Drew M. Pardoll (ORCID: https://orcid.org/0000-0001-6215-1013)
- Katherine M. Bever (ORCID: https://orcid.org/0000-0001-5230-4661)
- Hao Wang (ORCID: https://orcid.org/0000-0001-6489-6940)
- Ross C. Donehower (ORCID: https://orcid.org/0009-0001-4664-8916)
- Heather Davis Bruning (ORCID: https://orcid.org/0000-0003-2725-6172)
- Jayalaxmi Suresh Babu (ORCID: https://orcid.org/0009-0001-4919-1050)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Quantitative BioSciences (US)
- Sidney Kimmel Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0002
- Citations
- 8
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- Conquer Cancer Foundation
- Swim Across America
- National Cancer Institute
- Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University